Nuveen
ALDX icon

Nuveen’s Aldeyra Therapeutics ALDX Stock Holding History

Nuveen’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,266
Closed -$35.9K – 3739
2026
Q1 		$35.9K Sell
21,266
-86,954
-80% -$381K ﹤0.01% 3215
2025
Q4 		$561K Sell
108,220
-36,465
-25% -$187K ﹤0.01% 2830
2025
Q3 		$755K Buy
144,685
+37,980
+36% +$198K ﹤0.01% 2748
2025
Q2 		$409K Sell
106,705
-241,816
-69% -$625K ﹤0.01% 2947
2025
Q1 		$10M Buy
348,521
+218,797
+169% +$1.29M ﹤0.01% 1551
2024
Q4 		$647K Hold
129,724
– – ﹤0.01% 2886
2024
Q3 		$699K Hold
129,724
– – ﹤0.01% 2896
2024
Q2 		$429K Hold
129,724
– – ﹤0.01% 3043
2024
Q1 		$424K Hold
129,724
– – ﹤0.01% 3022
2023
Q4 		$455K Sell
129,724
-56,252
-30% -$174K ﹤0.01% 3037
2023
Q3 		$1.24M Buy
185,976
+56,523
+44% +$419K ﹤0.01% 2483
2023
Q2 		$1.09M Buy
+129,453
New +$1.28M ﹤0.01% 2621
2022
Q2 		– Sell
-237,359
Closed -$1.14M – 3235
2022
Q1 		$1.14M Buy
237,359
+662
+0.3% +$2.64K ﹤0.01% 2772
2021
Q4 		$1.55M Sell
236,697
-12,238
-5% -$93.3K ﹤0.01% 2691
2021
Q3 		$2.13M Sell
248,935
-99,190
-28% -$910K ﹤0.01% 2644
2021
Q2 		$3.94M Buy
+348,125
New +$4.19M ﹤0.01% 2362
2020
Q2 		– Sell
-61,063
Closed -$151K – 3272
2020
Q1 		$151K Sell
61,063
-78,319
-56% -$352K ﹤0.01% 3031
2019
Q4 		$810K Buy
139,382
+64,863
+87% +$375K ﹤0.01% 2757
2019
Q3 		$393K Buy
74,519
+8,826
+13% +$47.5K ﹤0.01% 3006
2019
Q2 		$394K Buy
+65,693
New +$494K ﹤0.01% 3073

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Nuveen's ALDX Position: Q2 2026 in Review

Nuveen sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 21,266 shares — an estimated $35.9K sold.

Nuveen first reported a position in ALDX in Q2 2019 and held it in 20 quarters. The position peaked at $10M in Q1 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Nuveen reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nuveen sold 21,266 Aldeyra Therapeutics shares in Q2 2026, an estimated $35.9K.
  • Nuveen first reported a position in Aldeyra Therapeutics in Q2 2019 and held it in 20 quarters.
  • Nuveen's Aldeyra Therapeutics position peaked at $10M in Q1 2025.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.